Iveric Bio Inc ISEE:NASDAQ

Last Price$12.15NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$12.11 (119)
Ask (Size)$12.16 (2)
Day Low / HighN/A - N/A
Volume1.1 M
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Iveric Bio Inc ( NASDAQ )

Price: $12.15
Change: -0.39 (3.11%)
Volume: 1.1 M
4:00PM ET 1/21/2022
 
 

Protagonist Therapeutics Inc ( NASDAQ )

Price: $29.33
Change: -2.48 (7.80%)
Volume: 1.1 M
4:00PM ET 1/21/2022
 
 

Sorrento Therapeutics Inc ( NASDAQ )

Price: $3.81
Change: -0.36 (8.75%)
Volume: 12.4 M
4:00PM ET 1/21/2022
 
 

Morphic Holding Inc ( NASDAQ )

Price: $40.01
Change: -0.35 (0.87%)
Volume: 223.5 K
4:00PM ET 1/21/2022
 
 

Celldex Therapeutics Inc ( NASDAQ )

Price: $27.87
Change: -1.29 (4.42%)
Volume: 686.7 K
4:00PM ET 1/21/2022
 

Read more news Recent News

Insider Sell: Iveric Bio
5:16PM ET 1/04/2022 MT Newswires

Keith Westby, Senior Vice President & COO, on December 31, 2021, sold 12,278 shares in Iveric Bio (ISEE) for $201,265. Following the Form 4 filing with the...

Insider Sell: Iveric Bio
5:16PM ET 1/04/2022 MT Newswires

David Francis Carroll, Senior Vice President, CFO and Treasurer, on December 31, 2021, sold 15,819 shares in Iveric Bio (ISEE) for $259,310. Following the...

IVERIC bio Names Tony Gibney Chief Business and Strategy Officer
5:15PM ET 12/13/2021 MT Newswires

IVERIC bio (ISEE) said late Monday Tony Gibney has been appointed as chief business and strategy officer, effective immediately. Most recently, Gibney was...

--HC Wainwright Adjusts Price Target on Iveric Bio to $26 From $20, Keeps Buy Rating
7:17AM ET 11/10/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionIVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY. View company web site for more details
AddressFive Penn Plaza
New York, New York 10001
Phone+1.212.845.8200
Number of Employees35
Recent SEC Filing01/11/20228-K
Chief Executive Officer & DirectorGlenn P. Sblendorio
PresidentPravin U. Dugel
Chief Operating Officer & Senior Vice PresidentKeith Westby
Chief Financial Officer, Treasurer & Senior VPDavid F. Carroll

Company Highlights

Price Open$12.48
Previous Close$12.54
52 Week Range$4.96 - 19.32
Market Capitalization$1.4 B
Shares Outstanding114.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.12
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-59.01%

Analyst Ratings as of 10/25/2021

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset